Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420004 · ClinicalTrials.gov registry record · Phase 2
A Study for Participants With Major Depression
A Phase 2 study of Major Depressive Disorder, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 469
- Enrollment target
- 7
- Study locations
NCT00420004 is a Phase 2 study of Major Depressive Disorder that has completed, run by Eli Lilly and Company. The registered enrollment target is 469 participants, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (25% higher). The trial reports 7 study locations across 4 states.
The verdict
NCT00420004, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 469 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Escitalopram
- DRUG LY2216684
Study Locations (7)
Other
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Bucharest
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Cluj-Napoca
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Lasi
Pennsylvania
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Allentown
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Media
Florida
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Orlando
Kansas
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Prairie Village
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420004
The ClinicalTrials.gov registry entry for NCT00420004 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 469 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (25% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00420004 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Other, Pennsylvania, Florida.
Frequently Asked Questions
What is clinical trial NCT00420004 about?
NCT00420004 is a clinical study titled "A Study for Participants With Major Depression". This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.
What is the current status of trial NCT00420004?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 469 participants. The study started on 2006-12. Estimated completion is 2008-03.
What conditions does trial NCT00420004 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00420004?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), LY2216684 (DRUG).
Who is sponsoring clinical trial NCT00420004?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00420004 being conducted?
This trial has 7 study locations across Florida, Kansas, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.